Safety of β-adrenergic blocker washout period in clinical trials
- 27 May 2009
- journal article
- Published by Wiley in Acta Ophthalmologica Scandinavica
- Vol. 75 (1) , 94-95
- https://doi.org/10.1111/j.1600-0420.1997.tb00259.x
Abstract
We prospectively evaluated the safety of the washout period from topical beta-adrenergic blockers prior to clinical drug trials. In 30 consecutive patients optic disc parameters (neural rim, optic disc, peripapillary halo and atrophy areas, and venous/arterial diameters) did not change following washout (p > 0.05). Likewise, the mean defect and pattern standard deviation (Humphrey 30-2) did not change following washout (p > 0.05). This study suggests, generally, the safety of the washout period prior to clinical drug trials.Keywords
This publication has 2 references indexed in Scilit:
- The Efficacy of Apraclonidine as an Adjunct to Timolol TherapyArchives of Ophthalmology (1950), 1995
- The Effects of Withdrawal of Timolol in Chronically Treated Glaucoma PatientsOphthalmology, 1988